shutterstock_1569359980_sundry_photography
Sundry Photography / Shutterstock.com
25 June 2020Americas

Gilead expands oncology business with Pionyr deal

Gilead Sciences has begun a potential takeover of  Pionyr Immunotherapeutics after it agreed to pay $275 million for a 49.9% equity stake in the cancer research company.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
2 June 2020   Gilead Sciences has persuaded the US Patent Trial and Appeal Board to review an antiviral patent owned by the University of Minnesota.
Generics
14 May 2020   Gilead has agreed to license its antiviral remdesivir to five generic makers for distribution during the COVID-19 pandemic.

More on this story

Americas
2 June 2020   Gilead Sciences has persuaded the US Patent Trial and Appeal Board to review an antiviral patent owned by the University of Minnesota.
Generics
14 May 2020   Gilead has agreed to license its antiviral remdesivir to five generic makers for distribution during the COVID-19 pandemic.

More on this story

Americas
2 June 2020   Gilead Sciences has persuaded the US Patent Trial and Appeal Board to review an antiviral patent owned by the University of Minnesota.
Generics
14 May 2020   Gilead has agreed to license its antiviral remdesivir to five generic makers for distribution during the COVID-19 pandemic.